A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections

BMC Infectious Diseases

Mark Wilcox²  Glenn Tillotson¹  Roger Echols³  Emma Best²  Neil Robinson⁴  Richard Vickers⁴ 

[1] TranScrip Partners LLC, Downingtown, PA, USA;Microbiology, Leeds Teaching Hospitals & University of Leeds, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK;753 Westport Road, Easton 06612, CT, USA;Summit PLC, 85b Park Drive, Milton Park, Abingdon, Oxford OX14 4RY, UK

关键词: CDAD;    CDI;    Gut microbiota;    Safety;    Phase 1;    SMT19969;   

Others  :  1135701
DOI  :  10.1186/s12879-015-0759-5

 received in 2014-03-31, accepted in 2015-01-15,  发布年份 2015

【 摘 要 】

Background

Clostridium difficile infection (CDI) is a leading cause of diarrhoea in health care settings with symptoms ranging from mild and self-limiting to life threatening. SMT19969 is a novel, non-absorbable antibiotic currently under development for the treatment of CDI. Here we report the results from a Phase I study.

Methods

A double-blind, randomized, placebo-controlled study assessing safety and tolerability of single and multiple oral doses of SMT19969 in healthy volunteers. Pharmacokinetic assessments included blood and faecal sampling. The effect of food on systemic exposure and analysis of the gut microbiota were also included.

Results

Fifty-six healthy male subjects were enrolled. Following single oral doses of up to 2,000 mg in the fasted state, plasma concentrations of SMT19969 were generally below the lower limit of quantification. In the fed state levels ranged from 0.102 to 0.296 ng/mL after single dosing and after repeat dosing at Day 10 from 0.105 to 0.305 ng/mL. Following single and multiple oral doses of SMT19969, mean daily faecal concentrations increased with increasing dose level and were significantly above the typical MIC range for C. difficile (0.06-0.5 μg/mL). At 200 mg BID, mean (± SD) faecal concentrations of 1,466 (±547) μg/g and 1,364 (±446) μg/g were determined on days 5 and 10 of dosing respectively. No notable metabolites were detected in faeces. Overall, all doses of SMT19969 were well tolerated both as single oral doses or BID oral doses for 10 days. The majority (88%) of adverse events (AEs) were classified as gastrointestinal disorders and were mild in severity, resolving without treatment. The gut microbiota was analysed in the multiple dose groups with minimal changes observed in the bacterial groups analysed except for total clostridia which were reduced to below the limit of detection by day 4 of dosing.

Conclusions

Oral administration of SMT19969 was considered safe and well tolerated and was associated with negligible plasma concentrations after single and multiple doses. In addition, minimal disruption of normal gut microbiota was noted, confirming the highly selective spectrum of the compound. These results support the further clinical development of SMT19969 as an oral therapy for CDI.

Trial registration

Current Controlled Trials. ISRCTN10858225 webcite.

【 授权许可】

   
2015 Vickers et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Rupnik M, Wilcox MH, Gerding DN: Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7(7):526-536.
• [2]Bartlett JG: Antibiotic Associated Diarrhea. N. Engl. J. Med. 2002, 346(5):334-339.
• [3]Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al.: The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23(3):529-549.
• [4]He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, et al.: Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013, 45(1):109-113.
• [5]Kelly CP: Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012, 18(Suppl 6):21-27.
• [6]Kelly CP, Lamont JT: Clostridium difficile—More Difficult Than Ever. N Engl J Med 2008, 359(18):1932-1940.
• [7]Cornely OA: Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect 2012, 18(Suppl 6):28-35.
• [8]Peterfreund GL, Vandivier LE, Sinha R, Marozsan AJ, Olson WC, Zhu J, et al.: Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile. PLoS One 2012, 7(10):e46966.
• [9]Rea MC, Dobson A, O’Sullivan O, Crispie F, Fouhy F, Cotter PD, et al.: Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 2011, 108(Suppl 1):4639-4644.
• [10]Louie TJ, Emery J, Krulicki W, Byrne B, Mah M: OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009, 53(1):261-263.
• [11]Zar FA, Bakkanagari SR, Moorthi KM, Davis MB: A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease Severity. Clin Infect Dis 2007, 45(3):302-307.
• [12]Bolton RP, Culshaw MA: Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986, 27(10):1169-1172.
• [13]Baines SD, O’Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, et al.: Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008, 62(5):1046-1052.
• [14]Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ: Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008, 52(7):2403-2406.
• [15]Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al.: Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med 2011, 364(5):422-431.
• [16]Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al.: Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12(4):281-289.
• [17]Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV: Comparative in vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-positive and Gram-negative Aerobic and Anaerobic Intestinal Flora Isolates. Antimicrob Agents Chemother 2013, 57(10):4872-4876.
• [18]Vickers R, Tinsley J, Storer R, Wilson F, Dorgan C, Wren S, et al.: SMT19969 – A Novel Antibiotic for C. difficile Infection C. difficile Growth Inhibition, Spectrum of Activity and Resistance Development. In Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. American Society of Microbiology, Washington, DC, USA; 2011. Abstract B-1194
• [19]Vickers RJ, Storer R, Tinsley J, Wilson F, Robinson N: SMT19969: Preclinical Safety and Pharmacokinetics of a Novel Antibiotic for Clostridium difficile Infection. In European Congress on Clinical Microbiology and Infectious Diseases. Berlin. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland; 2013. Abstract P1656
• [20]Weiss W, Pulse M, Vickers R: In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection. Antimicrob Agents Chemother 2014, 58(10):5714-5718.
• [21]Committee for Medicinal Products for Human Use: Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. European Medicines Agency, London, UK; 2007.
• [22]Baines SD, Freeman J, Wilcox MH: Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005, 55(6):974-982.
• [23]Lewis SJ, Heaton KW: Stool Form Scale as a Useful Guide to Intestinal Transit Time. Scand J Gastroenterol 1997, 32(9):920-924.
• [24]Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH: SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother 2014, 70(1):182-189.
• [25]Skraban J, Dzeroski S, Zenko B, Mongus D, Gangl S, Rupnik M: Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PLoS One 2013, 8(2):e58005.
• [26]Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, et al.: Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 2012, 80(1):62-73.
• [27]Naaber P, Smidt I, Stsepetova J, Brilene T, Annuk H, Mikelsaar M: Inhibition of Clostridium difficile strains by intestinal Lactobacillus species. J Med Microbiol 2004, 53(Pt 6):551-554.